Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers want to see if ruxolitinib works well as a treatment for T-cell large granular lymphocytic leukemia (T-LGLL). T-LGLL is a rare cancer of white blood cells called lymphocytes. The people in this study have T-LGLL that keeps growing even with treatment.
Researchers are doing this study to see how well sotorasib gets into metastatic brain tumors. The people in this study have tumors in the brain that have spread there from other parts of the body. They are planning to have the brain metastases removed with surgery. In addition, their tumors have a mutation (change) in the KRAS gene (KRAS G12C+).
Researchers are comparing different treatments for non-muscle invasive bladder cancer (NMIBC). The people in this study have NMIBC that keeps growing after treatment with an immunotherapy called Bacillus Calmette-Guerin (BCG). They do not want surgery to remove the bladder (radical cystectomy).
Researchers want to find the best dose of BBO-10203 to use in people with advanced solid tumors. The people in this study have one of these types of cancer that has spread (metastasized):
The purpose of this study is to assess the safety and effectiveness of the investigational drug repotrectinib in children and young adults with solid tumors that have continued to grow or spread despite treatment. Repotrectinib works by targeting and blocking certain proteins that play a role in cancer growth. Some of these proteins are controlled by the ALK, ROS1, NTRK1, NTRK2, and NTRK3 genes. Researchers also think that combining repotrectinib with the chemotherapy drugs irinotecan and temozolomide may make the treatment more effective.
Researchers in this study want to determine if combining the drug venetoclax with standard chemotherapy may be more effective than standard chemotherapy alone in children and adolescents with relapsed acute myeloid leukemia (AML). Venetoclax blocks Bcl-2, a protein that helps cancer cells to survive and resist the effects of cancer treatments. By blocking Bcl-2, venetoclax may kill cancer cells and/or make other treatments more effective.
This study is evaluating the safety and effectiveness of combination chemotherapy, surgery, and radiation therapy in children and young adults with newly diagnosed stage II-IV diffuse anaplastic Wilms' tumors (DAWT) or favorable histology Wilms' tumors (FHWT) that have come back (relapsed).
The purpose of this study is to compare two different approaches to surgery for children and adults with osteosarcoma (bone cancer) that has spread (metastasized) to the lungs. Participants will be randomly assigned to one of two techniques:
Studies have shown that patients with newly diagnosed localized non-germinomatous germ cell tumors (NGGCT) of the brain or spinal cord whose disease responds well to chemotherapy before receiving radiation therapy are more likely to be free of the disease for a longer time than patients in whom chemotherapy is less effective.
Researchers in this study are seeking the best dose of CBL0137 in people with solid tumors. They also want to see how well it works against certain cancers.
